HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have been given a consensus rating of “Hold” by the five ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $16.80.

Several equities research analysts have commented on the stock. Wall Street Zen cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Weiss Ratings cut shares of HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 1st. Bank of America dropped their target price on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, March 10th. Finally, Morgan Stanley set a $13.60 target price on shares of HUTCHMED in a research note on Thursday, May 28th.

HUTCHMED Stock Performance

Shares of HUTCHMED stock opened at $10.63 on Wednesday. The business has a fifty day simple moving average of $13.35 and a 200-day simple moving average of $14.00. HUTCHMED has a fifty-two week low of $10.40 and a fifty-two week high of $19.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.83 and a current ratio of 4.96.

Institutional Investors Weigh In On HUTCHMED

Several large investors have recently modified their holdings of HCM. Amundi grew its holdings in shares of HUTCHMED by 4.0% in the 1st quarter. Amundi now owns 232,246 shares of the company’s stock worth $3,474,000 after acquiring an additional 8,916 shares during the last quarter. Janney Montgomery Scott LLC purchased a new position in HUTCHMED in the 1st quarter worth about $365,000. State Street Corp raised its holdings in HUTCHMED by 1.2% during the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after buying an additional 3,801 shares during the period. Renaissance Technologies LLC lifted its stake in HUTCHMED by 3.0% during the fourth quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock valued at $1,798,000 after buying an additional 3,900 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of HUTCHMED by 157.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 55,969 shares of the company’s stock worth $746,000 after buying an additional 34,248 shares during the period. 8.82% of the stock is owned by institutional investors.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.